Does Rallies show Form 4 insider transactions for CAI?

Yes. Rallies tracks CAI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CAI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CAI. It does not provide personalized investment advice.

CAI (Caris Life Sciences, Inc. Common Stock) Stock Analysis - Insider Trades

Caris Life Sciences, Inc. Common Stock (CAI) is a publicly traded Healthcare sector company. As of May 21, 2026, CAI trades at $15.73 with a market cap of $4.27B and a P/E ratio of -2.47. CAI moved +4.88% today. Year to date, CAI is -40.55%; over the trailing twelve months it is flat. Its 52-week range spans $14.19 to $42.50. Analyst consensus is strong buy with an average price target of $27.92. Rallies surfaces CAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CAI stock inside the company?

Recent CAI insider activity includes Vacirca Jeff L bought 31.05K, Power Luke Thomas sold 60.85K, Power Luke Thomas sold 1.40K, Denton John Russel bought 4.18K, and Spetzler David Baxley bought 400. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CAI Key Metrics

Key financial metrics for CAI
Metric	Value
Price	$15.73
Market Cap	$4.27B
P/E Ratio	-2.47
EPS	$-6.27
Dividend Yield	0.30%
52-Week High	$42.50
52-Week Low	$14.19
Volume	2.50M
Avg Volume	0
Revenue (TTM)	$907.29M
Net Income	$33.98M
Gross Margin	0.00%

Recent CAI Insider Trades

Vacirca Jeff L bought 31.05K (~$501.43K) on May 11, 2026.
Power Luke Thomas sold 60.85K (~$1.62M) on Dec 11, 2025.
Power Luke Thomas sold 1.40K (~$38.02K) on Dec 11, 2025.
Denton John Russel bought 4.18K (~$100.79K) on Nov 7, 2025.
Spetzler David Baxley bought 400 (~$9.54K) on Nov 7, 2025.

Latest CAI News

Caris Lookback Program Flags 13,293 Patients for 87 New Targeted Therapies — May 15, 2026
Caris Life Sciences Posts 79% Q1 Revenue Growth to $216.2M, Gets Perform Rating — May 8, 2026
Caris Life Sciences Seeks NY Authorization for Caris Assure Blood-Based Test — May 8, 2026
Caris Life Sciences Q1 Revenue Jumps 79% to $216M, Gross Margin 65% — May 7, 2026
Caris Life Sciences Unveils AI Test Predicting Early and Late Breast Cancer Recurrence in 3 Days — May 5, 2026

CAI Analyst Consensus

12 analysts cover CAI: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.92.

Common questions about CAI

Who is trading CAI stock inside the company?: Recent CAI insider activity includes Vacirca Jeff L bought 31.05K, Power Luke Thomas sold 60.85K, Power Luke Thomas sold 1.40K, Denton John Russel bought 4.18K, and Spetzler David Baxley bought 400. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CAI?: Yes. Rallies tracks CAI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CAI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CAI. It does not provide personalized investment advice.